{"id":742128,"date":"2011-04-15T06:01:00","date_gmt":"2011-04-15T06:01:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-2011-non-gaap-eps-target\/"},"modified":"2026-08-10T13:01:18","modified_gmt":"2026-08-10T17:01:18","slug":"merck-reaffirms-2011-non-gaap-eps-target","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-2011-non-gaap-eps-target\/","title":{"rendered":"Merck Reaffirms 2011 Non-GAAP EPS Target"},"content":{"rendered":"<p>WHITEHOUSE STATION, N.J.&#8211;(BUSINESS WIRE)&#8211;Following the Merck and Johnson &amp; Johnson settlement announcement today,        Merck (NYSE: MRK) said that it continues to expect 2011 non-GAAP        earnings per share (EPS) to be in the range of $3.64 to $3.76, excluding        certain items. The 2011 non-GAAP EPS target range excludes the $500        million one-time payment to Centocor as well as related tax impacts of        the arbitration resolution, purchase accounting adjustments,        restructuring costs and merger-related expenses. The 2011 GAAP EPS        target range includes the entire impact of the arbitration settlement        and is now expected to be in the range of $1.89 to $2.17. A        reconciliation of anticipated 2011 EPS as reported in accordance with        GAAP to non-GAAP EPS that excludes certain items is provided in the        table below.     <\/p>\n<p>       Merck also continues to expect full year 2011 revenue to grow in the low        to mid-single digit percent range from the base of $46.0 billion in the        full year of 2010.     <\/p>\n<p>       &#8220;We are pleased that the purposeful and focused steps we have taken in        the first half of 2011 will allow us to maintain our prior 2011 non-GAAP        financial targets \u2013 including revenue and EPS \u2013 while absorbing the        ongoing impact of the settlement during the remainder of the year,&#8221; said        Kenneth C. Frazier, president and chief executive officer of Merck.        &#8220;Looking ahead, the ongoing and future launches of Simponi in countries        across Europe give us additional opportunities.&#8221;     <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tr>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">           <b>Full-Year 2011<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           <b>GAAP EPS<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">           <b>$1.89 to $2.17<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignm bwalignl bwsinglebottom\">           EPS difference<sup>1<\/sup>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">           $1.75 to $1.59         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignb bwalignl bwsinglebottom\">           <b>Non-GAAP EPS that excludes items listed below<\/b>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignc bwsinglebottom\">           <b>$3.64 to $3.76<\/b>         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td>           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td>         <\/td>\n<td>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignt bwalignc bwsinglebottom\">           <b>Full-Year 2011<\/b>         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">           Purchase accounting adjustments         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignr bwsinglebottom\">           $4,800 to $4,500         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">           Costs related to restructuring programs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignr bwsinglebottom\">           900 to 700         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">           Arbitration settlement payment         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignr bwsinglebottom\">           500         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">           Merger-related costs         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignr bwsinglebottom\">\n<p class=\"bwcellpmargin\">             200 to 100           <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">           Net decrease in income before taxes         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignr bwsinglebottom\">           6,400 to 5,800         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">           Income tax (benefit)<sup>2<\/sup>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignr bwsinglebottom\">           (980) to (860)         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">           Decrease in net income         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignr bwsinglebottom\">           $5,420 to $4,940         <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwvertalignt bwalignl bwsinglebottom\">           <b>EPS difference<\/b><sup><b>1<\/b><\/sup>         <\/td>\n<td class=\"bwsinglebottom\">           \u00a0         <\/td>\n<td class=\"bwpadl0 bwvertalignm bwalignr bwsinglebottom\">           <b>$1.75 to $1.59<\/b>         <\/td>\n<\/tr>\n<\/table>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships that        donate and deliver our products to the people who need them. For more        information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com&amp;esheet=6685724&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=1&amp;md5=49cba0ce8d41cdc41750399bd40cffdd\">www.merck.com<\/a>.     <\/p>\n<p>       <b>Forward-Looking Statement<\/b>     <\/p>\n<p>       This news release includes \u201cforward-looking statements\u201d within the        meaning of the safe harbor provisions of the United States Private        Securities Litigation Reform Act of 1995. Such statements may include,        but are not limited to, statements about the benefits of the merger        between Merck and Schering-Plough, including future financial and        operating results, the combined company\u2019s plans, objectives,        expectations and intentions and other statements that are not historical        facts. Such statements are based upon the current beliefs and        expectations of Merck\u2019s management and are subject to significant risks        and uncertainties. Actual results may differ from those set forth in the        forward-looking statements.     <\/p>\n<p>       The following factors, among others, could cause actual results to        differ from those set forth in the forward-looking statements: the        possibility that the expected synergies from the merger of Merck and        Schering-Plough will not be realized, or will not be realized within the        expected time period; the impact of pharmaceutical industry regulation        and health care legislation; the risk that the businesses will not be        integrated successfully; disruption from the merger making it more        difficult to maintain business and operational relationships; Merck\u2019s        ability to accurately predict future market conditions; dependence on        the effectiveness of Merck\u2019s patents and other protections for        innovative products; the risk of new and changing regulation and health        policies in the U.S. and internationally and the exposure to litigation        and\/or regulatory actions.     <\/p>\n<p>       Merck undertakes no obligation to publicly update any forward-looking        statement, whether as a result of new information, future events or        otherwise. Additional factors that could cause results to differ        materially from those described in the forward-looking statements can be        found in Merck\u2019s 2010 Annual Report on Form 10-K and the company\u2019s other        filings with the Securities and Exchange Commission (SEC) available at        the SEC\u2019s Internet site (<a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=6685724&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=2&amp;md5=619313b89bf0dea35c73c4a526ee09da\">www.sec.gov<\/a>).     <\/p>\n<p>       _____________________________________     <\/p>\n<p>       <sup>1<\/sup> Represents the difference between calculated GAAP EPS and        calculated non-GAAP EPS, which may be different than the amount        calculated by dividing the impact of the excluded items by the weighted        average shares.     <\/p>\n<p>       <sup>2<\/sup> Represents an estimated income tax (benefit) expense        relating to the reconciling items.     <\/p>\n<p><p>       Merck<br \/>Media Contact:<br \/>David Caouette, 908-423-3461<br \/>or<br \/>Investor        Contact:<br \/>Joe Romanelli, 908-423-5088<br \/>Carol Ferguson,        908-423-4465     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Following the Merck and Johnson &amp; Johnson settlement announcement today, Merck (NYSE: MRK) said that it continues to expect 2011 non-GAAP earnings per share (EPS) to be in the range of $3.64 to $3.76, excluding certain items. The 2011 non-GAAP EPS target range excludes the $500 million one-time payment to Centocor as well as related tax impacts of the arbitration resolution, purchase accounting adjustments, restructuring costs and merger-related expenses. The 2011 GAAP EPS target range includes the entire impact of the arbitration settlement and is now expected to be in the range of $1.89 to $2.17. A reconciliation of anticipated 2011 EPS as reported in accordance with GAAP to non-GAAP EPS that excludes certain items is provided in the table below. Merck also continues to expect full year 2011 revenue to grow in the low to mid-single digit percent range from the base of $46.0 billion in the full year of 2010. &#8220;We are pleased that the purposeful and focused steps we have taken in the<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[52,289],"class_list":["post-742128","news_item","type-news_item","status-publish","hentry","tag-financial-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Reaffirms 2011 Non-GAAP EPS Target - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-2011-non-gaap-eps-target\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Reaffirms 2011 Non-GAAP EPS Target - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Following the Merck and Johnson &amp; Johnson settlement announcement today, Merck (NYSE: MRK) said that it continues to expect 2011 non-GAAP earnings per share (EPS) to be in the range of $3.64 to $3.76, excluding certain items. The 2011 non-GAAP EPS target range excludes the $500 million one-time payment to Centocor as well as related tax impacts of the arbitration resolution, purchase accounting adjustments, restructuring costs and merger-related expenses. The 2011 GAAP EPS target range includes the entire impact of the arbitration settlement and is now expected to be in the range of $1.89 to $2.17. A reconciliation of anticipated 2011 EPS as reported in accordance with GAAP to non-GAAP EPS that excludes certain items is provided in the table below. Merck also continues to expect full year 2011 revenue to grow in the low to mid-single digit percent range from the base of $46.0 billion in the full year of 2010. &quot;We are pleased that the purposeful and focused steps we have taken in the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-2011-non-gaap-eps-target\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-reaffirms-2011-non-gaap-eps-target\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-reaffirms-2011-non-gaap-eps-target\\\/\",\"name\":\"Merck Reaffirms 2011 Non-GAAP EPS Target - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2011-04-15T06:01:00+00:00\",\"dateModified\":\"2026-08-10T17:01:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-reaffirms-2011-non-gaap-eps-target\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-reaffirms-2011-non-gaap-eps-target\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-reaffirms-2011-non-gaap-eps-target\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Reaffirms 2011 Non-GAAP EPS Target\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Reaffirms 2011 Non-GAAP EPS Target - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-2011-non-gaap-eps-target\/","og_locale":"en_US","og_type":"article","og_title":"Merck Reaffirms 2011 Non-GAAP EPS Target - Merck.com","og_description":"Following the Merck and Johnson &amp; Johnson settlement announcement today, Merck (NYSE: MRK) said that it continues to expect 2011 non-GAAP earnings per share (EPS) to be in the range of $3.64 to $3.76, excluding certain items. The 2011 non-GAAP EPS target range excludes the $500 million one-time payment to Centocor as well as related tax impacts of the arbitration resolution, purchase accounting adjustments, restructuring costs and merger-related expenses. The 2011 GAAP EPS target range includes the entire impact of the arbitration settlement and is now expected to be in the range of $1.89 to $2.17. A reconciliation of anticipated 2011 EPS as reported in accordance with GAAP to non-GAAP EPS that excludes certain items is provided in the table below. Merck also continues to expect full year 2011 revenue to grow in the low to mid-single digit percent range from the base of $46.0 billion in the full year of 2010. \"We are pleased that the purposeful and focused steps we have taken in the","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-2011-non-gaap-eps-target\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:18+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-2011-non-gaap-eps-target\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-2011-non-gaap-eps-target\/","name":"Merck Reaffirms 2011 Non-GAAP EPS Target - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2011-04-15T06:01:00+00:00","dateModified":"2026-08-10T17:01:18+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-2011-non-gaap-eps-target\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-2011-non-gaap-eps-target\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-reaffirms-2011-non-gaap-eps-target\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Reaffirms 2011 Non-GAAP EPS Target"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"d5f30342-9e6d-439e-8e42-b58cd546b579","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742128","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742128\/revisions"}],"predecessor-version":[{"id":3679264,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742128\/revisions\/3679264"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742128"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742128"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}